VIR-2482
VIR-2482 is a monoclonal antibody targeting influenza A hemagglutinin (HA). VIR-2482 is generated by introducing LS mutations (M428L/N434S) into the Fc region of MEDI8852 (HY-P991446). VIR-2482 binds to the conserved HA stem epitope across all 18 influenza A HA subtypes, neutralizes a broad spectrum of H1N1 and H3N2 strains, binds to FcγRIIIa, FcγRIIa and C1q, and induces antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. VIR-2482 reduces morbidity and mortality caused by seasonal influenza A strains and provides prophylactic protection in mice. VIR-2482 can be used in research related to influenza A disease.
For research use only. We do not sell to patients.
- Purity : 97.85%
-
Storage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
In Vitro
VIR-2482 shows that influenza A virus isolates from study participants retain susceptibility to it in vitro, with fold changes in EC50 ranging from 0.23 to 2.55 relative to subtype reference strains[1].
VIR-2482 binds to all 18 influenza A HA subtypes and neutralizes a broad panel of H1N1 and H3N2 viruses spanning nearly 100 years of evolution, with key contact residues showing >98.8% conservation in H1N1 and H3N2 sequences from 2009-2019[2].
VIR-2482 retains the ability to engage human FcγRIIIa, FcγRIIa, and C1q, and maintains functional ADCC and CDC activity in vitro despite containing half-life extending Fc mutations[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Accession
Target
influenza A virus hemagglutinin HA
Conjugated
Unconjugated
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
Application
ELISA, FACS, Functional assay
Chemical Information
-
Appearance Liquid
-
Color Colorless to light yellow
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Tan SK, et al. A Randomized, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of VIR-2482 in Healthy Adults for Prevention of Influenza A Illness (PENINSULA). Clin Infect Dis. 2024;79(4):1054-1061. [Content Brief]
[3]. Plotnik D, et al. A phase 1 study in healthy volunteers to investigate the safety, tolerability, and pharmacokinetics of VIR-2482: a monoclonal antibody for the prevention of severe influenza A illness. Antimicrob Agents Chemother. 2024;68(4):e0127323. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
VIR-2482 Related Classifications
HY-P992482 Related Classifications
Powered by Bioz
Keywords
- VIR-2482
- VIR2482
- VIR 2482
- Drug Derivative
- Influenza Virus
- Fc Receptor (FcR)
- Complement System
- Drug derivative
- Fc Receptor
- H1N1 PR8
- Balb/c mice
- influenza A hemagglutinin
- C1q
- FcγRIIIa
- complement-dependent cytotoxicity
- H3N2 HK/68
- FcγRIIa
- neonatal Fc receptor
- antibody-dependent cell-mediated cytotoxicity
- Inhibitor
- inhibitor
- inhibit